Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
2.47 CAD | +5.56% | -3.14% | +124.55% |
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
David Elsley
FOU | Founder | - | 19.01.17 |
Director of Finance/CFO | - | 16.08.18 | |
Kelly Narine
CTO | Chief Tech/Sci/R&D Officer | - | 01.10.20 |
Andrew Hamer
CTO | Chief Tech/Sci/R&D Officer | 62 | 29.03.21 |
Bernard Lim
COO | Chief Operating Officer | - | 03.12.20 |
Trevor Burns
IRC | Investor Relations Contact | - | 01.01.17 |
John Geddes
PRN | Corporate Officer/Principal | - | 01.01.22 |
Corporate Officer/Principal | - | 01.06.15 | |
Thomas Moffatt
PRN | Corporate Officer/Principal | - | 01.03.19 |
Anne Tomalin
LAW | General Counsel | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
David Elsley
FOU | Founder | - | 19.01.17 |
Jennifer Chao
BRD | Director/Board Member | 54 | 15.03.22 |
Michael Willner
BRD | Director/Board Member | 57 | 07.09.21 |
Director of Finance/CFO | - | 16.08.18 | |
Peter Pekos
BRD | Director/Board Member | - | 15.12.17 |
Chairman | - | 20.08.18 | |
Teri Loxam
BRD | Director/Board Member | 51 | 19.05.22 |
Colin Stott
BRD | Director/Board Member | 57 | 03.12.19 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 68 283 708 | 65 484 158 ( 95,90 %) | 0 | 95,90 % |
Unternehmenskontakt
Cardiol Therapeutics, Inc.
2265 Upper Middle Road East Suite 602
L6H 0G5, Oakville
+289 910 0850
http://www.cardiolrx.comSektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+124.55% | 116 Mio. | |
-1.42% | 41.35 Mrd. | |
+42.15% | 40.38 Mrd. | |
+1.97% | 39.05 Mrd. | |
-14.19% | 26.67 Mrd. | |
+1.82% | 24.07 Mrd. | |
-24.55% | 18.36 Mrd. | |
-4.07% | 11.68 Mrd. | |
+21.36% | 11.6 Mrd. | |
+8.20% | 11.15 Mrd. |
- Börse
- Aktien
- A2PA9E Aktie
- Unternehmen Cardiol Therapeutics Inc.